Short answer
Rapport Therapeutics, Inc. (RAPP) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $20M with net income of −$20M.
Q1 2026 key financials · XBRL
- Revenue
- $20M
- Net income
- −$20M
- +17.5% YoY
- Operating margin
- -121.1%
- EPS (diluted)
- −$0.42
- +38.2% YoY
Source: XBRL data from the Rapport Therapeutics, Inc. (RAPP) Q1 2026 10-Q on SEC EDGAR. USD.
Rapport Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly triggered risk identified; section presents existing clinical-stage biotechnology risks
- Liquidity risk: $476.8 million cash, equivalents and short-term investments expected to fund operations into the second half of 2029
- Financial concentration risk: Janssen obligations include up to $76.0 million development milestones and $40.0 million sales milestones
- Regulatory risk: FDA placed RAP-219’s DPNP IND on clinical hold, removed in December 2025, followed by deferred investment
- Operational risk: RAP-219 remains central to development plans, with no products approved for commercial sale or product revenue generated
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rapport Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.